Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Rhea-AI Summary

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focused on pioneering advanced cancer treatments, has announced its participation in two major investor conferences this April.

The company will attend the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, offering one-on-one meetings with investors. Additionally, they will present at the Stifel Virtual Targeted Conference Forum on April 8, 2025, from 3:30-3:55 p.m. ET. Both events will be held virtually.

SEATTLE, March 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

24th Annual Needham Virtual Healthcare Conference - 1x1s Only
Date: Monday, April 7, 2025
Location: Virtual

Stifel Virtual Targeted Conference Forum – Company Presentation
Date: Tuesday, April 8, 2025
Time: 3:30-3:55 p.m. ET
Location: Virtual

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs are in Phase 1/2a imaging and therapy trials in the U.S. for the treatment of metastatic melanoma and neuroendocrine tumors, respectively. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary ²¹²Pb generator, to deliver patient-ready products for clinical trials and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatment applications for cancers throughout the body; the ability of the Company's proprietary technology utilizing the alpha emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting moieties provide the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary ²¹²Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact.

These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com

FAQ

When is Perspective Therapeutics (CATX) presenting at the Stifel Virtual Conference in April 2025?

Perspective Therapeutics (CATX) will present at the Stifel Virtual Targeted Conference Forum on April 8, 2025, from 3:30-3:55 p.m. ET.

Which investor conferences is CATX attending in April 2025?

CATX is participating in two conferences: the 24th Annual Needham Virtual Healthcare Conference on April 7 and the Stifel Virtual Targeted Conference Forum on April 8, 2025.

Will CATX offer one-on-one meetings with investors at the Needham Healthcare Conference?

Yes, CATX will be available for one-on-one meetings with investors at the Needham Virtual Healthcare Conference on April 7, 2025.

Are the CATX investor conferences in April 2025 in-person or virtual events?

Both investor conferences are virtual events, with no in-person attendance required.